然而，令人失望的是，仅有20-42%的这些新获批抗肿瘤药物，能够达到由ASCO和ESMO设定的临床获益标准，即延长总生存期超过2.5个月。另外40%新批的抗肿瘤药物延长生存期2周至2.5个月，有30%新批的抗肿瘤药物未能改善总生存期。

香港, 2024年9月13日 - (亚太商讯) — ...

- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma ...

英矽智能创始人兼首席执行官Alex Zhavoronkov博士表示：“ ...

▎药明康德内容团队编辑  Join Dr. Peijun Ma’s Lab at St. Jude Children’s Research Hospital (Memphis, TN, U.S.)We are expanding rapidly and seeking passionate, self-driven postdoctoral researchers and graduate stu ...

STING通路的激活在肿瘤免疫中是一把双刃剑：STING的激活不仅促进T细胞浸润和杀伤，同时也被证明诱导免疫抑制分子如PD-L1和IDO的表达，高剂量的STING激动剂可诱导T细胞凋亡。 目前，免疫检查点抑制剂（immune checkpoint inhibitor, ICI）在晚期非小细胞肺癌患者临床实践 ...

HANGZHOU, Sept. 21 (Xinhua) -- China's space station has gained initial results in the field of space medicine that will contribute to future manned lunar landings and other deep space exploration ...

On Thursday, Beijing Tiantan Hospital, which is affiliated to Capital Medical University, announced the foundation of a joint laboratory of Amyotrophic Lateral Sclerosi(ALS) during the 2024 China Inte ...